Its tumor suppressor activity is supported by mice with a null mutation of IRF8 developing a CML-like syndrome [34] and lack of IRF8 expression in patients with chronic and acute myeloid leukemia [35]. Here, IRF8 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.